Samsung Biologics Expands Globally Through Acquisition
Samsung Biologics is expanding its global footprint through the acquisition of PolyPeptide Group for $1.8 billion to enhance capabilities in peptide therapeutics and diversify geographically.
More World news
- SpaceX Partners with Qualcomm to Launch Starlink Mobile Cellular Service
- Blast Resources Appoints Andy Yackulic as CEO to Lead Uranium Exploration
- FMC Corporation Shares Decline 13% in Thursday Trading
- U.S. Stock Indices Decline Following Nvidia CEO Jensen Huang's Resignation
- EY Report Outlines Three Fundamental Shifts Required for Future-Ready Health Systems by 2040
- ProLift Garage Doors Expands Franchise Services and Support Initiatives
- Pomerantz Law Firm Investigates Cerebras Systems Inc. Over Potential Securities Fraud
- CEZ Reports 9M Revenue Growth and 24% Increase in Net Income
- BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera
- U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO